Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Parl Panel Moots...

    Parl Panel Moots One-Time Settlement of Drug Overpricing Cases

    Written by savita thakur thakur Published On 2016-05-01T10:40:54+05:30  |  Updated On 1 May 2016 10:40 AM IST
    Parl Panel Moots One-Time Settlement of Drug Overpricing Cases

    A Parliamentary panel has suggested a one-time settlement of drug overpricing cases that regulator NPPA is currently fighting with the pharmaceutical companies.


    Drug price regulator National Pharmaceutical Pricing Authority (NPPA) has been trying to recover a whopping Rs 4,551 crore including interests from various pharma companies for overcharging as of February this year. As much as 82 per cent of this amount is under litigation.


    The standing committee on Ministry of Chemicals and Fertilisers in its report tabled in Parliament noted that NPPA had prepared a draft for one-time settlement with an aim of quick recovery of overcharged amount that was sent to the Department of Pharmaceuticals for its formal approval.


    "The earlier proposal sent two years back to Ministry of Finance was not approved. The committee, therefore recommend that the department should take up the matter with Ministry of Finance again by strongly putting its case for one-time settlement scheme with full justification," the report added.


    The Parliamentary panel also said it is dismayed to note that since inception of NPPA, there are 1,389 cases as on February 29, 2016. Where demand notices have been issued to pharmaceutical companies for recovery of overcharged amount.


    NPPA mandate is to fix or revise the prices of controlled bulk drugs, formulations and to enforce prices and availability of the medicines in the country. It has been entrusted with fixation of prices of scheduled drugs under the Drug (Price Control) Order, 1995 (DPCO) 1995 and DPCO 2013.


    The regulator also monitors prices of decontrolled drugs in order to keep them at reasonable levels.

    1995DPCODrug (Price Control) OrderDrug overpricingNational Pharmaceutical Pricing AuthorityNPPA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok